XML 31 R16.htm IDEA: XBRL DOCUMENT v3.22.2.2
Organization, Basis of Presentation and Summary of Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Schedule of Fair Value And Amortized Cost of Marketable Securities

The fair value and amortized cost of marketable securities by major security type is as follows:

 

 

 

September 30, 2022

 

(in thousands)

 

Amortized Cost

 

 

Unrealized Gains

 

 

Unrealized Losses

 

 

Fair Value

 

Money market funds

 

$

37,094

 

 

$

 

 

$

 

 

$

37,094

 

U.S. government securities

 

 

43,120

 

 

 

 

 

 

(681

)

 

 

42,439

 

Non-U.S. government securities

 

 

3,022

 

 

 

 

 

 

(41

)

 

 

2,981

 

Corporate debt securities

 

 

29,514

 

 

 

 

 

 

(284

)

 

 

29,230

 

Commercial paper

 

 

49,659

 

 

 

 

 

 

 

 

 

49,659

 

Total

 

$

162,409

 

 

$

 

 

$

(1,006

)

 

$

161,403

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Classified as:

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents

 

 

 

 

 

 

 

 

 

 

$

37,094

 

Marketable securities

 

 

 

 

 

 

 

 

 

 

 

124,309

 

Total

 

 

 

 

 

 

 

 

 

 

$

161,403

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2021

 

(in thousands)

 

Amortized Cost

 

 

Unrealized Gains

 

 

Unrealized Losses

 

 

Fair Value

 

Money market funds

 

$

33,239

 

 

$

 

 

$

 

 

$

33,239

 

U.S. government securities

 

 

36,322

 

 

 

 

 

 

(130

)

 

 

36,192

 

Non-U.S. government securities

 

 

11,194

 

 

 

 

 

 

(12

)

 

 

11,182

 

Corporate debt securities

 

 

39,495

 

 

 

 

 

 

(52

)

 

 

39,443

 

Commercial paper

 

 

31,466

 

 

 

 

 

 

 

 

 

31,466

 

Total

 

$

151,716

 

 

$

 

 

$

(194

)

 

$

151,522

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Classified as:

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents

 

 

 

 

 

 

 

 

 

 

$

33,239

 

Marketable securities

 

 

 

 

 

 

 

 

 

 

 

118,283

 

Total

 

 

 

 

 

 

 

 

 

 

$

151,522

 

 

Schedule of Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities included the following:

 

(in thousands)

 

September 30, 2022

 

 

December 31, 2021

 

Research and development costs

 

$

1,559

 

 

$

1,570

 

Compensation and benefit costs

 

 

1,993

 

 

 

2,403

 

Accrued professional fees

 

 

862

 

 

 

363

 

Other

 

 

308

 

 

 

358

 

Total accrued expenses and other current liabilities

 

$

4,722

 

 

$

4,694

 

Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share The Company excluded the following potential shares of common stock, presented based on amounts outstanding at each period end, from the computation of diluted net loss attributable to common stockholders per share of common stock for the periods indicated because including them would have had an anti-dilutive effect:

 

 

 

September 30,

 

 

 

2022

 

 

2021

 

Options to purchase common stock

 

 

4,760,085

 

 

 

3,556,043

 

Unvested restricted stock units

 

 

100,880

 

 

 

 

Shares issuable under employee stock purchase plan

 

 

112,757

 

 

 

 

Total

 

 

4,973,722

 

 

 

3,556,043